<DOC>
	<DOCNO>NCT00110877</DOCNO>
	<brief_summary>Study TMC114-C214 randomize , control , open-label trial compare efficacy , safety tolerability TMC114 boost low dose ritonavir ( RTV ) versus Kaletra ( LPV ) /RTV lopinavir-na√Øve treatment-experienced HIV-1 infected patient .</brief_summary>
	<brief_title>TMC114-C214 : Trial TMC114 Administered With Low Dose Ritonavir ( RTV ) HIV-1 Infected Treatment Experienced Patients</brief_title>
	<detailed_description>Study TMC114-C214 randomize ( patient assign different treatment group base chance ) , control , open-label trial compare efficacy ( effectiveness ) , safety tolerability TMC114 boost low dose ritonavir ( RTV ) versus Kaletra ( LPV ) /RTV treatment-experienced HIV-1 infected patient . This research study look safety TMC114 effectiveness reduce amount HIV ( viral load ) blood . People include study receive either Non-Nucleoside Reverse Transcriptase Inhibitors ( NNRTIs ) Protease Inhibitors ( PIs ) . The duration study approximately 106 week , include 4 6 week screening period , 96-week treatment period , 4-week follow-up period . TMC114 300mg orange tablet 2 tablet take mouth twice day 1 tablet Ritonavir . Kaletra ( LPV/RTV ) either tablet capsule take twice day . The oral capsule contain 133.3 mg LPV , 33.3 mg RTV film-coated tablet available oral administration strength 200 mg lopinavir 50 mg ritonavir . Dosing medication occur 96 week randomly assign either TMC114 Kaletra .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patient document HIV1 infection Treatment Antiretroviral regimen ( contain least 2 NRTIs combination least 1 NNRTI and/or 1 PI ) least 12 week Plasma HIV1 RNA &gt; 1000 copies/mL General medical condition interfere assessment completion trial Patients investigational Antiretroviral part current regimen , follow exception applicable ( depend local regulatory approval ) tenofovir , emtricitabine , atazanavir , fosamprenavir Previous current use lopinavir , enfuvirtide ( T20 ) , tipranavir TMC114 Life expectancy le 6 month Pregnant breastfeed Females childbearing potential willing use effective nonhormonal birth control method willing continue practice birth control method least 14 day end treatment period Patients significantly decrease liver function decompensation , irrespective liver enzyme level Participation investigational trial without prior approval sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>TMC114-C214</keyword>
</DOC>